Deep dives, evidence grades, and clinical tools, all in one place.
Practice Signal
Immune Checkpoint Inhibitors in GI and Liver Cancers
Oncology Pharmacy3 sources · Updated Aug 18, 2026
This review helps pharmacists distinguish practice-changing checkpoint inhibitor regimens from hypothesis-generating signals and anticipate the toxicity patterns that follow the chemotherapy backbone versus the immune component.
Bottom Line
PD-1/PD-L1 checkpoint inhibitors have moved from metastatic salvage to validated first-line and adjuvant use across GI and liver cancers, but the strength of evidence and the role of the chemotherapy backbone differ sharply by tumor type and treatment setting.
0.50
hazard ratio, recurrence or death
0.76
hazard ratio, OS cholangiocarcinoma
23.6% vs 11.5%
24-month OS, TOPAZ-1
Preferred
first-line chemo-immunotherapy status
State of Play
Immune checkpoint inhibition is now embedded in first-line care for advanced cholangiocarcinoma and in adjuvant care for deficient mismatch repair (dMMR) stage III colon cancer, while its role after curative hepatocellular carcinoma (HCC) resection remains investigational. Across settings the recurring theme is that most severe toxicity tracks with the cytotoxic backbone, whereas immune-related adverse events (irAEs) accumulate during checkpoint inhibitor exposure.
🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Want the full review?
Subscribe to PharmD Signal for the complete evidence synthesis and practice recommendations on every topic, plus every deep analysis we publish.
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.